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Previous research demonstrated that following amygdala kindling, animals showed 
a heightened sensitivity to morphine’s convulsive effects and an exaggerated Straub 
tail response. These effects were evident to 3 months after their last convulsion and 
could be blocked by naloxone pretreatment. The present paper extends these findings 
by demonstrating that animals given metrazol or electroshock (ECS) convulsions also 
showed an enhanced morphine response that was blocked by naltrexone. Both metrazol- 
and ECStreated animals convulsed in response to doses of morphine that produced 
little or no effect in control animals. In addition, it was shown that brain damage 
induced by electrode implantation or neocortex penetration by skull screws also in- 
creased an animal’s sensitivity to morphine even in the absence of prior convulsions. 
This effect, however, could not be blocked by naltrexone. Finally, as opiate receptors 
vary with the diurnal rhythm, we determined that following amygdala kindling, animals 
are more sensitive to morphine’s convulsive action during their dark phase when 
receptor number and sensitivity are highest. The results indicated that seizure proneness, 
whether induced by a history of prior convulsions or brain damage, increased sensitivity 
to morphine. This effect may be due to a change in opiate receptors only when prior 
convulsions have occurred. 
INTRODUCTION 
Previous research in our laboratory demonstrated that kindling produces 
long-lasting changes in responsiveness to opiates ( 11, 12). Typically only very 
high, and usually lethal doses, of morphine are able to induce convulsions 
in normal mice. After undergoing amygdala kindling, mice show a high 
incidence of clonic convulsions and an exaggerated Straub tail response to 
relatively low doses of morphine. Changes in morphine responsiveness can 
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be detected to 3 months after an animal’s last stimulation-induced convulsion. 
Moreover, the morphine-induced convulsions observed in kindled animals 
do not appear to be a nonspecific action of the drug, as they can be blocked 
by small doses of naloxone. 
In our earlier study, we also observed that animals kindled in the neocortex 
showed the same changes in morphine responsiveness as seen after amygdala 
kindling (11). It seemed, therefore, that the change was not specific to kindling 
of a particular brain structure, and might occur after a regimen of convulsions 
induced by means that are not known to produce an epileptogenic brain 
focus. To test this possibility, we determined whether or not repeated metrazol 
or electroshock (ECS) convulsions produce the changes observed to follow 
kindling with brain electrodes. As our results demonstrated that morphine 
responsiveness was also changed after metrazol and ECS convulsions, we 
determined if these effects could be blocked by naltrexone pretreatment. 
Although the results obtained aher metrazol and ECS convulsions extended 
our earlier observations, the role of kindling in producing the enhanced 
responsiveness to morphine became less certain. There are a number of 
reports indicating that kindling occurs with metrazol, as initially subconvulsive 
doses after repeated injections will produce convulsions (4). It is less clear, 
however, whether or not repeated ECS produces a kindling effect. Although 
it has been claimed in the clinical literature that kindling does not occur 
with repeated ECS (20), more recent reports indicate that under certain 
conditions “ECS kindling” does occur in rats (15) and in mice (16). These 
discrepancies may be due to species differences, or to differences in the interval 
between electroshocks typically used clinically and in animal research. 
In view of the unresolved controversy over the question of “ECS kindling,” 
it is not clear whether the increased sensitivity to morphine is reflecting an 
enhanced seizure-proneness or a relatively long-lasting change produced by 
generalized convulsions. This question was pursued by testing the sensitivity 
to morphine of animals that never had a convulsion, but were suspected of 
being more seizure-prone because they had experienced brain damage (1). 
We tested animals after either electrode implantation, or penetration of the 
skull and cortex by the screws normally used to attach electrodes to the head. 
As the results revealed that brain damage without convulsions increased 
sensitivity to morphine, we tested the capacity of naltrexone to block this 
effect. 
Last, even though we demonstrated that the change that follows amygdala 
kindling, metrazol, or ECS could be blocked by naloxone or naltrexone, it 
was not obvious whether the change in responsiveness to morphine was due 
to modification of opiate receptors or to some other brain changes that 
lowered convulsion thresholds and could be accessed through opiate receptor 
mechanisms. Although this is a difficult question to answer in a definitive 
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way, as a first step, we determined whether or not the probability of inducing 
convulsions in kindled animals was correlated with reported changes in opiate 
receptors. As studies have indicated that rats show a greater sensitivity to 
morphine’s analgesic and locomotor effects (2, 5) as well as an increased 
receptor number (13) during the dark phase of their day-night cycle, we 
examined the effects of diurnal rhythm on morphine-induced convulsions 
in kindled mice. 
METHODS 
General Methods 
All animals used in the following experiments were adult C57BL/6J mice 
either bought from Jackson Laboratories, Bar Harbor, Maine, or bred in our 
laboratory from Jackson stock. The animals were maintained on a 12-h 
light: 12-h dark cycle with food and water available ad libitum. The injections 
of morphine sulfate, metrazol, naltrexone, or saline were intraperitoneal. All 
drug data points were based on a minimum of six animals with the one 
exception noted below. With the exception of experiment IV, the morphine 
tests were administered 1 to 5 h after the beginning of the dark phase. 
The range of doses was based on the results from pilot experiments. When 
a range was established, appropriate doses were selected for the studies reported 
here. The animals were randomly assigned to a drug condition and tested 
only once. The percentage of animals showing a generalized convulsion, 
including clonic limb movements and falling, was recorded for each drug 
condition in each of the experiments. 
Experiment I: Comparison of the Eflect of Seizures Induced by Amygdala 
Kindling, Metrazol, or Electroconvulsive Shock on Morphine Sensitivity 
Surgery, Amygdala Kindling, and Morphine Dose-Response Curve. A total 
of 56 mice was implanted with bipolar electrodes in the amygdala. With the 
skull level, the stereotaxic coordinates were 1.5 mm posterior to bregma, 3.5 
mm lateral, and 4.5 mm below the dorsal surface of the skull. Using those 
coordinates, electrodes typically were placed in the center of the amygdala 
complex. The electrodes consisted of two twisted, Teflon-coated, stainless- 
steel wires (0.1524 mm diameter) soldered to microminiature pins (Winchester 
Co. 8456). 
Following recovery from surgery the animals were assigned to one of two 
groups; one group received brain stimulation (N = 31) and the other group 
served as handled, implanted controls (N = 25). The experimental animals 
were stimulated once daily with a l-s duration, 50 PA, 60 Hz sine wave 
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current until they showed seven consecutive generalized convulsions (stages 
5 through 7). The kindled convulsions were rated according to the following 
scale (14): 1 = mouth movements, 2 = head nodding, 3 = clonus, 4 = clonus 
plus rearing, 5 = generalized convulsion (GC) plus rearing and falling, 6 
= GC plus repeated rearing and falling, 7 = GC plus repeated rearing and 
falling followed by running. 
Three days after their last convulsion, the kindled animals were given one 
of four morphine doses (3, 10, 17, or 25 mg/kg, i.p.) and observed 90 min 
for the appearance of morphine-induced convulsions. The control animals 
were handled identically to the kindled animals and tested with either 10, 
25, 60, or 100 mg/kg morphine. 
Metrazol Procedure and Dose-Response Curve. Unpublished work in our 
laboratory had shown that when a constant dose of metrazol is administered 
daily, C57 mice have progressively more severe convulsions and generally 
die after their third or fourth convulsion. We therefore used a dose titration 
procedure which allowed us to give animals seven generalized metrazol con- 
vulsions. All the experimental mice (N = 18) received an initial screening 
dose of metrazol (50 mg/kg, i.p.). Those animals that convulsed were given 
45 mg/kg metrazol the following day. If they continued to show convulsions 
the dose was reduced by 5 mg/kg daily until they had seven convulsions. If 
a convulsion was not elicited on 2 consecutive days the dose was increased 
by 5 mg/kg every 2 days until a convulsive dose was reached. On subsequent 
days, the dose reduction procedure described above was repeated. Those 
animals not showing a convulsion to the screening dose of metrazol for 2 
consecutive days received progressively larger doses on subsequent days until 
a convulsion was elicited. The dose of metrazol was then titrated as described. 
Using this procedure, animals attained the criterion of seven generalized 
convulsions within 13 to 27 days of metrazol treatment. Control animals (N 
= 21) were handled identically to the metrazol-treated animals except they 
were injected daily with saline. Three days alter the last metrazol convulsion, 
the experimental animals were tested for morphine-induced convulsions with 
either 25,60, or 100 mg/kg morphine. Control animals were similarly tested 
with either 100, 300, or 600 mg/kg morphine. 
Electroconvulsive Shock Procedure and Morphine Dose-Response Curve. 
Mice (N = 20) received seven corneal electroshock convulsions and were 
tested 3 days later for morphine-induced convulsions. The procedure consisted 
of delivering electricity (6.5 mA, 0.5 s) via two saline-soaked gauze pads 
attached to wooden dowels and placed against the cornea of each eye. Control 
animals (N = 2 1) were handled identically except that they were not shocked. 
The experimental animals were tested with either 25, 60, or 100 mg/kg 
morphine, and the controls were injected with either 100, 300, or 600 
mg/kg morphine. 
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Experiment II. Naltrexone Blockade of Morphine-Induced Convulsions 
in Metrazol-treated, Electroconvulsed, or Chronically 
Implanted and Naive Animals 
Mice were given seven metrazol convulsions, seven ECS convulsions, or 
amygdala electrode implantation (without stimulation) as described in ex- 
periment I. Three days after their last convulsion or 28 days after electrode 
implantation, the animals were pretreated with various doses of naltrexone 
(0.0, 0.1, 1 .O, 3.0, 10.0, or 30.0 mg/kg) 5 min prior to receiving 100 mg/kg 
morphine. We used this dose of morphine because it induced convulsions 
in approximately 70% of the ECS- and metrazol-treated animals and in 86% 
of implanted animals (experiment I). 
Naive mice (N = 14) were pretreated with either 60 mg/kg naltrexone or 
saline 5 min prior to 600 mg/kg morphine to test whether or not the con- 
vulsions observed in naive animals after very large doses of morphine are 
mediated by opiate receptors. The dose of 60 mg/kg naltrexone alone never 
produced convulsions in C57 mice (personal observation). 
Experiment III. Brain Damage and Morphine Sensitivity 
Brain damage was produced by screwing stainless-steel skull screws (O/80) 
into the skull over the parietal, frontal, and occipital regions of mice (N 
= 25). The three screws protruded through the skull and penetrated ap- 
proximately 0.85 mm into the underlying cortex. All screws were immediately 
removed after insertion. Control mice (N = 21) had a scalp incision made 
under the same anesthetia (phenobarbital, 80 mg/kg) and were otherwise 
handled similarly to the experimental animals. The experimental and control 
mice were given either 100, 300, or 450 mg/kg morphine and tested 28 days 
postsurgery for morphine-induced convulsions. The selection of the 28-day 
interval was based on the average interval between surgery and morphine 
testing of the amygdala kindled animals. 
Experiment IV. Effects of Day-Night Cycle on Morphine-Induced 
Convulsions in Kindled Mice 
Mice (N = 19) were maintained on a 12-h on: 12-h off light-dark cycle 
with the lights going on at 0500 h. All animals were implanted with amygdala 
electrodes as described in experiment I and were stimulated once daily between 
0900 and 1200 h. Three days after reaching the criterion of seven consecutive 
generalized convulsions, the animals were randomly divided into three groups. 
Two groups were injected with either 30 mg/kg (N = 7) or 60 mg/kg (N = 6) 
morphine between 0800 and 1100 h (light phase) and the third group 
(N = 6) was injected with 30 mg/kg between 1800 and 2000 h (dark phase). 
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The animals were observed for morphine-induced convulsions during a 90- 
min test period. 
RESULTS 
Amygdala kindled, ECS, or metrazol convulsions produced a change in 
morphine responsiveness that was evident when animals were tested 3 days 
after their last convulsion (Fig. 1). Morphine convulsions were induced in a 
dose-dependent manner in kindled mice, with a maximal effect at 25 
mg/kg (89% of mice convulsed). In contrast, none of the implanted control 
mice showed a convulsion after this dose of morphine. In fact, it took four 
times this dose of morphine to produce a comparable effect (86% of mice 
convulsed) in the implanted control animals. 
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FIG. 1. Percentage of animals convulsing in response to different doses of morphine administered 
3 days after seven amygdala-kindled, metrazol or electroconvulsive shock (ECS) convulsions. 
All control animals were handled equivalently and amygdala-kindled controls had implanted 
electrodes. All data points are based on six or more animals; the total number of animals is in 
parentheses. 
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to morphine. Sixty-six percent of the animals previously treated with metrazol 
and 7 1% of the animals given ECS convulsed after a dose of 100 mg/kg 
morphine. In contrast, this dose of morphine never produced a convulsion 
in the unimplanted saline-injected or handled controls. Unimplanted control 
mice required doses of 300 mg/kg or greater before showing convulsions to 
morphine. The morphine-induced convulsions observed in the unimplanted 
control mice were usually lethal (12 of 13 animals) whereas those seen in 
ECS- and metrazol-treated animals never resulted in death. Similarly, doses 
of morphine necessary to induce convulsions in kindled (25 mg/kg) and in 
implanted control mice (100 mg/kg) never resulted in the animal’s death. 
Electrode implantation produced an increased sensitivity to morphine as 
is seen by comparing the response of implanted mice to either the unimplanted 
handled or saline-injected controls. Eighty-six percent of the implanted con- 
trols convulsed to a 100 mg/kg dose of morphine, whereas none of the 
handled or saline-injected controls convulsed at this dose (Fig. 1). Further, 
even the brain damage produced by the insertion and removal of skull screws 
altered the sensitivity of animals to morphine (Fig. 2). A greater percentage 
of brain damaged animals convulsed compared with their controls at each 
dose of morphine tested, with the largest difference occurring at 300 mg/kg. 
Even at the 450 mg/kg dose, where the percentage of animals convulsing 
was similar, the brain damaged animals showed more severe convulsions, 
resulting in death in six of the seven animals tested. In contrast, only two 
of the five control mice that convulsed at this dose died. 
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FIG. 2. Percentage of animals convulsing in response to different doses of morphine administered 
28 days after insertion and removal of skull screws (see text for details). Controls were anesthetized 
and the scalp incised, and then tested with morphine 28 days later. All data points are based on 
six or more animals. Numbers in ( ) = total numbers used. 
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The morphine-induced convulsions observed in the ECS and metrazol- 
treated animals were blocked by naltrexone pretreatment (Fig. 3). A dose of 
3.0 or 10.0 mg/kg naltrexone blocked the convulsive effects of 100 mg/kg 
morphine in the ECS- and metrazol-treated animals, respectively. In contrast, 
doses of 1 .O, 10.0, or 30.0 mg/kg naltrexone failed to block the convulsions 
induced by morphine in animals with amygdala electrodes that were not 
kindled. Doses of 10 and 30 mg/kg naltrexone did, however, block the ste- 
reotyped running and Straub tail response that is normally seen with this 
dose of morphine. Similar results were observed in naive mice, in which 
naltrexone (60 mg/kg) was able to block the stereotyped running and Straub 
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FIG. 3. Percentage of animals convulsing in response to 100 mg/kg morphine administered 
5 min after different doses of naltrexone. Metrazol-treated and ECS groups were tested 3 days 
after their last convulsion. Animals with amygdala electrodes were handled daily and tested 28 
days after surgery. All data points are based on six or more animals except for the metrazol 
group pretreated with 0.1 mg/kg naltrexone (N = 4). Numbers in ( ) = total numbers used. 
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Figure 4 shows that the sensitivity of kindled mice to morphine-induced 
convulsions varied with the day-night cycle. Whereas 83% of the mice tested 
with 30 mg/kg morphine during the dark phase convulsed, only 29% of the 
mice tested in the light phase with the same dose of morphine convulsed 
(chi square = 3.9, P < 0.05). The effects seen with the 30 mg/kg dose in the 
dark phase were consistent with the dose-response relationship found in 
experiment 1. The finding that 83% of the animals convulsed with a dose 
of 60 mg/kg morphine when tested during the light phase argues for a twofold 
change in sensitivity with the day-night cycle. 
DISCUSSION 
These results indicate that repeated ECS, metrazol, or kindled convulsions 
produce long-lasting changes in morphine responsiveness. The animals in 
each of these treatment groups showed a changed morphine responsiveness 
and convulsed at doses that produced no response in control animals. In an 
earlier publication (11) we reported that the induced morphine convulsions 
observed in kindled animals could be blocked by naloxone. The present study 
has shown that naltrexone pretreatment blocks the morphine-induced con- 
vulsions observed in metrazol- and ECS-treated animals. 
Our results also show that electrode implantation or damage induced by 
insertion and removal of skull screws can increase an animal’s sensitivity to 
morphine even without any prior convulsions. The morphine-induced con- 
vulsions observed in electrode-implanted animals are not, however, blocked 
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FIG. 4. Percentage of amygdala-kindled animals convulsing after 30 or 60 mgjkg morphine 
administered during the dark or light phase of their diurnal cycle. All data points are based on 
six or more animals. Numbers in ( ) = total numbers used. 
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by naltrexone pretreatment. This suggests that the change in morphine sen- 
sitivity observed to follow brain damage, in contrast to that seen after repeated 
convulsions, may not be due to changes in opiate receptors. Naltrexone was 
similarly unable to block the convulsions observed in naive animals produced 
by lethal doses of morphine. This is consistent with the findings of others 
who have been unable to block morphine’s convulsive effects (7). These 
results may be explained by assuming that large doses of systemic morphine 
induce both opiate receptor-dependent and nonspecific effects. Naltrexone, 
while antagonizing the opiate receptor effects of morphine, does not antagonize 
the nonopiate convulsant effects observed in the naive and electrode-implanted 
animals. 
The changes we observed in morphine responsiveness that follow electrode 
implantation or screw penetration of the neocortex may be the result of 
changes in GABA systems. Morphine has been reported (2 1) to inhibit GABA 
systems and such an effect might trigger convulsions, particularly in seizure- 
prone animals. If this were the case, naltrexone would not be expected to 
block these morphine-induced convulsions. Consistent with this speculation 
is the report that opiate alkaloids and peptides antagonized GABA responses 
and this effect was not reversible by naloxone (21). 
There are a number of different mechanisms that might explain the change 
in morphine responsiveness that follows repeated convulsions. It is unlikely 
that the changes in morphine responsiveness are due only to damage of the 
blood-brain barrier, as animals that have undergone electrode implantation, 
where the blood-brain barrier is certainly damaged, should have also shown 
a naltrexone-reversible change in morphine responsiveness. Yet, as is seen 
from our results, naltrexone failed to block the morphine-induced convulsions 
observed in implanted animals. A more probable explanation is that kindling, 
ECS, and metrazol produce a change in morphine responsiveness by increasing 
either opiate receptor number or affinity. The literature provides some support 
for such an explanation, as repeated ECS was reported to produce an increase 
in opiate receptor number in rats (9). It was also reported that ECS (10) and 
amygdala kindling ( 19) elevate enkephalin, and this finding may also explain 
the present results. 
It is difficult to say at present which of the opiate receptor subpopulations 
might be changed by repeated convulsions. The doses of morphine used in 
our preparations are probably sufficiently large to stimulate more than just 
mu opiate receptors. Moreover, we recently found that kindled mice are 
more sensitive to ethylketazocine, a kappa receptor agonist, and these effects 
can be blocked by naloxone pretreatment ( 12). This raises the possibility that 
kindling or repeated convulsions induce changes in both mu and kappa 
receptors. Other investigators have implicated delta receptors in seizure 
mechanisms. For example, Frenk et al. (8) found that intraventricular in- 
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jections of the delta receptor agonists, met- and leu-enkephalin, induce seizures 
at smaller doses than morphine. Similarly, Holaday et al. (9) reported that 
repeated ECS produced an increase in delta receptor number without changing 
receptor affinity. Based on our work and that of others (17), it seems likely 
that more than one and possibly all the opiate receptors participate in the 
mediation of seizures. 
The change in morphine sensitivity with the day-night cycle is consistent 
with the notion that kindling produces changes in opiate receptors. Kindled 
mice were more sensitive to morphine-induced convulsions during the dark 
phase, a time when opiate receptor numbers peak (13). Nonetheless, any 
suggestion of a causal relationship should be considered as very tentative 
at this time because of the many other processes that vary with the diur- 
nal cycle. 
Our result demonstrating an altered responsiveness to morphine that follows 
a history of convulsions or brain damage raises the possibility of devising a 
test of seizure-proneness. We are aware of the many problems in such an 
approach. Although morphine is clearly a convulsant in our animals, its 
actions are species-specific. For instance, morphine has been shown to have 
both pro- and anticonvulsant action in the rat and its effects may vary with 
the route of administration [see (6) for review]. Urea and Frenk (18) found 
that although morphine increased the latency of onset of metrazol convulsions, 
it also increased the number of convulsions observed. Similarly, although a 
large dose of morphine can reduce the behavioral aspects of kindled con- 
vulsions, it also increases the duration of the electrographic seizures (3). 
Although these opposing actions of morphine complicate the problem, it is 
certainly conceivable that a model could be developed which emphasizes the 
change in responsiveness of seizure-prone animals to this drug. For obvious 
reasons, such a model would have to use a more benign end-point to assess 
responsiveness to morphine than the induction of convulsions. 
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